OncoCyte Corporation – Consensus Indicates Potential -7.6% Downside

Broker Ratings

OncoCyte Corporation with ticker code (OCX) have now 7 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 8 and 2 with a mean TP of 4.71. With the stocks previous close at 5.1 this indicates there is a potential downside of -7.6%. The 50 day MA is 2.98 and the 200 moving average now moves to 1.88. The market capitalisation for the company is $429m. Visit the company website at: http://www.oncocyte.com

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index